Corival

Corival Life Sciences is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for patients with autoimmune and inflammatory diseases, with a primary focus on Celiac disease. The company's lead program centers on a potent and selective small molecule inhibitor of Transglutaminase 2, an enzyme that plays a central role in the pathogenesis of Celiac disease by deamidating gluten peptides. By targeting this key driver of the inflammatory response, Corival aims to provide a pharmacological solution for patients who continue to experience symptoms despite adhering to a gluten-free diet. The company is led by an experienced management team with a track record of successful drug development in the gastrointestinal and autoimmune sectors.